IKZF3 and Miyoshi myopathy: It selectively degrades IKZF1 and IKZF3 at sub-nanomolar concentrations, exhibiting significant efficacy against various MM and DLBCL cell lines and xenograft models, even against lenalidomide-resistant cells.